Harald Schmidt is Professor of Pharmacology & Personalised Medicine at the Faculty of Health, Medicine and Life Sciences at Maastricht University, Netherlands. He coordinates the Horizon 2020 program REPO-TRIAL and the Horizon Europe platform project in network medicine and drug repurposing, REPO4EU. Before, he had worked in Australia, Germany, and the USA in different academic and business leadership positions. These include a Chair of Monash University’s Centre for Vascular Health, Australia, different chairs in pharmacology, and director of a drug discovery CRO at TransMIT, Giessen, Germany. ERC Advanced Investigator and ERC PoC investigator. He also co-founded and, for two years, led as CEO of Vasopharm GmbH, a drug discovery company now entering into phase III clinical development. His research focuses on network medicine, cardiovascular and neurological disease mechanisms, target validation, drug repurposing, and biomarker discovery for precision medicine, including phase II clinical trials. Professor Schmidt has published over 200 peer-reviewed papers, reviews, books, and patents (Hirsch-index of 102; Google-Scholar: tinyurl.com/q4july7). He is Co-Editor in Chief of 'Network Medicine' and 'Drug Repurposing.'. He has been awarded the Roche Molecular Biochemicals Research Prize for Cell Biology, the Phoenix Research Prize in Pharmacy, the Pro Scientia Prize, and an ERC AdG.